Samuel Faught, MD
Radiation Oncology · Greenville, SCNPI 1659469476
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $817 and has fallen 67.6% since, to $264 in 2025.
Across 125 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$271
- Pfizer$170
- Seagen Inc.$158
- Merck$157
- Blue Earth Diagnostics$143
- AstraZeneca$137
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,441100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,441 in reported general payments places this provider in the 80th percentile of 72 radiation oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 24 | $459 |
| Memantine Hcl | 11 | $268 |
| Oxycodone Hcl | 13 | $204 |
| Tamsulosin Hcl | 24 | $138 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Greenville
- John OconnellGreenville$6K
- Emory McTyreGreenville$2K
- Michael GreenbaumGreenville$2K
- Shirnett MatthewsGreenville$2K
- Michael ZurenkoGreenville$940
- Jennifer VogelGreenville$222
- Daniel FriedSpartanburg$57K
- Clinton MedberyCharleston$37K
- Brian LallyCharleston$29K
- Kurt MeyerColumbia$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.